Department of Family Medicine, Health Promotion Center, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang-Si, Gyeonggi-do, Republic of Korea.
Bone. 2012 Dec;51(6):1008-15. doi: 10.1016/j.bone.2012.08.126. Epub 2012 Aug 30.
Hypertension and osteoporosis are prevalent in the elderly population. Treatments beneficial to both conditions would be helpful. We examined the protective effect of β-blockers (BBs) and their receptor selectivity against fractures compared to other antihypertensives.
A retrospective cohort was assembled using the Korean Health Insurance Review and Assessment Service database from January 2005 to June 2006. The cohort consisted of 501,924 patients (ages 65 and older) on single-drug therapy for hypertension. Participants were followed to either the date of the first fracture, date of death or end of the study period (30 June 2006), whichever came first. Cox's proportional hazard model was used to calculate the adjusted hazard ratio (aHR) and 95% confidence interval (CI) by sex, adjusting for confounders. Risk of fractures by BBs according to β1 selectivity was compared to non BBs measured in aHR.
Among 501,924 (65% female), the incidence density of fractures in non BB users was 29.3 and 48.2 per 1000 person-years for men and women, respectively, which was higher than in BB users (17.2 for men and 30.5 for women). Compared to BB users, non BB users showed an increased risk of all fracture [aHR 1.56 (95% CI, 1.42-1.72) in men and 1.44 (95% CI, 1.36-1.51) in women] and hip fracture [aHR 2.17 (95% CI 1.45-3.24) in men and 1.61 (95% CI 1.31-1.98) in women] after adjusting for confounding variables. Compared to BBs, the risks of all fractures in α-blockers, calcium channel blockers, diuretics, and renin-angiotensin-aldosterone system blockers were significantly higher (1.72, 1.77, 1.58, 1.29 in men; 2.11, 1.50, 1.46, 1.22 in women, respectively). Compared to non BBs, β1 selective BBs showed a lower risk of fracture (39% for men and 33% for women) after adjusting for confounding factors. On the contrary, non-selective BBs were not protective against fracture.
Our results suggested that β1 selective BBs reduce the risk of fractures compared to other classes of antihypertensives in an elderly population, which could have practical applications for strategies to control and prevent adverse outcomes from both hypertension and osteoporosis in this population.
高血压和骨质疏松症在老年人群中很常见。对两种疾病都有治疗作用的药物将是有益的。我们研究了β受体阻滞剂(BBs)及其受体选择性与其他降压药相比对骨折的保护作用。
使用 2005 年 1 月至 2006 年 6 月期间韩国健康保险审查和评估服务数据库,组建了一个回顾性队列。该队列包括 501924 名(年龄 65 岁及以上)接受单一药物治疗高血压的患者。参与者的随访时间为首次骨折发生日期、死亡日期或研究期结束日期(2006 年 6 月 30 日),以先到者为准。使用 Cox 比例风险模型,按性别调整混杂因素后,计算调整后的危险比(aHR)和 95%置信区间(CI)。通过 aHR 比较 BB 与非 BB 类药物的β1 选择性与骨折风险的关系。
在 501924 名患者中(65%为女性),非 BB 使用者的骨折发生率密度分别为男性 29.3 例/1000 人年和女性 48.2 例/1000 人年,高于 BB 使用者(男性 17.2 例/1000 人年,女性 30.5 例/1000 人年)。与 BB 使用者相比,非 BB 使用者全骨折风险增加[aHR 男性 1.56(95%CI,1.42-1.72),女性 1.44(95%CI,1.36-1.51)]和髋部骨折风险增加[aHR 男性 2.17(95%CI,1.45-3.24),女性 1.61(95%CI,1.31-1.98)],校正混杂因素后。与 BB 相比,α 受体阻滞剂、钙通道阻滞剂、利尿剂和肾素-血管紧张素-醛固酮系统阻滞剂的全骨折风险显著更高[aHR 男性 1.72、1.77、1.58、1.29,女性 2.11、1.50、1.46、1.22]。校正混杂因素后,与非 BB 相比,β1 选择性 BB 骨折风险降低(男性 39%,女性 33%)。相反,非选择性 BB 并不能预防骨折。
我们的研究结果表明,与其他降压药相比,β1 选择性 BB 可降低老年人群骨折风险,这可能对控制和预防该人群高血压和骨质疏松症的不良后果具有实际应用价值。